Inogen EV/EBIT INGN

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2016.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 35.6×; Apr 2022
10-year median: 61.7×
10-year range: 20.8× to 426×
Peer median: 12.5×

Inogen has no meaningful EV/EBIT today: it made an operating loss of $30.9M over the last twelve months.

It was last meaningful in Apr 2022, at 35.6×.

On the days it had one over the last ten years, its median was 61.7×, from 20.8× in Aug 2019 to 426× in Sep 2021.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2022	35.6×	35.6×	60.2×
2021	50.8×	43.8×	426×
2020	36.7×	25.8×	54.9×
2019	43.7×	20.8×	79.7×
2018	63.0×	58.9×	161×
2017	81.3×	58.5×	85.2×
2016	62.1×	47.8×	62.8×

Against its peers

Companies in Medical - Instruments & Supplies nearest Inogen's size, closest first, today.

Company	EV/EBIT
INGNInogen	n/m
PDEXPro DEX	16.0×
UTMDUtah Medical Products	6.0×
INFUInfuSystem	22.4×
KEQUKewaunee Scientific	7.2×
EMBCEmbecta	6.7×
TCMDTactile Systems Technology	13.3×
MDXGMimedx	51.6×
APTAlpha Pro Tech	8.2×
MOVMovado	11.8×
NEPHNephros	20.5×
Peer median	12.5×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Inogen

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.